vs
Side-by-side financial comparison of Healthcare Realty Trust Inc (HR) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Healthcare Realty Trust Inc is the larger business by last-quarter revenue ($279.0M vs $177.4M, roughly 1.6× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -0.0%, a 1.7% gap on every dollar of revenue. On growth, Healthcare Realty Trust Inc posted the faster year-over-year revenue change (5.9% vs 5.0%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -6.1%).
Duke Realty was a real estate investment trust (REIT) based in Indianapolis, Indiana, that invested in industrial properties. As of December 31, 2021, it owned or jointly controlled 548 primarily industrial properties containing 162.7 million rentable square feet. In October 2022, it was acquired by Prologis.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
HR vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $279.0M | $177.4M |
| Net Profit | $-56.0K | $2.9M |
| Gross Margin | — | — |
| Operating Margin | — | 3.9% |
| Net Margin | -0.0% | 1.6% |
| Revenue YoY | 5.9% | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.00 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $279.0M | $177.4M | ||
| Q4 25 | $286.3M | $196.9M | ||
| Q3 25 | $297.8M | $179.5M | ||
| Q2 25 | $297.5M | $181.1M | ||
| Q1 25 | $299.0M | $168.9M | ||
| Q4 24 | $309.8M | $187.3M | ||
| Q3 24 | $315.4M | $168.6M | ||
| Q2 24 | $316.3M | $178.0M |
| Q1 26 | $-56.0K | $2.9M | ||
| Q4 25 | $14.6M | — | ||
| Q3 25 | $-57.7M | $5.4M | ||
| Q2 25 | $-157.9M | $-4.8M | ||
| Q1 25 | $-44.9M | $4.8M | ||
| Q4 24 | $-108.2M | — | ||
| Q3 24 | $-93.0M | $-143.5M | ||
| Q2 24 | $-143.8M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | — | 1.2% | ||
| Q3 25 | — | 3.5% | ||
| Q2 25 | — | 4.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | — | -82.8% | ||
| Q2 24 | — | 15.9% |
| Q1 26 | -0.0% | 1.6% | ||
| Q4 25 | 183.4% | — | ||
| Q3 25 | -19.4% | 3.0% | ||
| Q2 25 | -53.1% | -2.7% | ||
| Q1 25 | -15.0% | 2.8% | ||
| Q4 24 | -1924.1% | — | ||
| Q3 24 | -29.5% | -85.1% | ||
| Q2 24 | -45.5% | 10.6% |
| Q1 26 | $0.00 | $0.07 | ||
| Q4 25 | $0.04 | $0.05 | ||
| Q3 25 | $-0.17 | $0.12 | ||
| Q2 25 | $-0.45 | $-0.11 | ||
| Q1 25 | $-0.13 | $0.10 | ||
| Q4 24 | $-0.34 | $0.38 | ||
| Q3 24 | $-0.26 | $-3.11 | ||
| Q2 24 | $-0.39 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $26.2M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.4B | $653.9M |
| Total Assets | $9.1B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $26.2M | $144.3M | ||
| Q4 25 | $26.2M | $238.4M | ||
| Q3 25 | $43.3M | $246.3M | ||
| Q2 25 | $25.5M | $445.9M | ||
| Q1 25 | $25.7M | $493.6M | ||
| Q4 24 | $68.9M | $484.6M | ||
| Q3 24 | $22.8M | $453.8M | ||
| Q2 24 | $41.8M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $3.9B | $372.2M | ||
| Q3 25 | $4.5B | $376.7M | ||
| Q2 25 | $4.7B | $580.5M | ||
| Q1 25 | $4.7B | $583.4M | ||
| Q4 24 | $4.7B | $585.3M | ||
| Q3 24 | $5.0B | — | ||
| Q2 24 | $5.1B | — |
| Q1 26 | $4.4B | $653.9M | ||
| Q4 25 | $4.6B | $693.1M | ||
| Q3 25 | $4.7B | $727.2M | ||
| Q2 25 | $4.8B | $757.8M | ||
| Q1 25 | $5.1B | $798.5M | ||
| Q4 24 | $5.2B | $778.3M | ||
| Q3 24 | $5.5B | $749.6M | ||
| Q2 24 | $5.9B | $879.3M |
| Q1 26 | $9.1B | $1.2B | ||
| Q4 25 | $9.2B | $1.3B | ||
| Q3 25 | $9.9B | $1.3B | ||
| Q2 25 | $10.2B | $1.5B | ||
| Q1 25 | $10.5B | $1.6B | ||
| Q4 24 | $10.7B | $1.6B | ||
| Q3 24 | $11.2B | $1.5B | ||
| Q2 24 | $11.8B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.85× | 0.54× | ||
| Q3 25 | 0.96× | 0.52× | ||
| Q2 25 | 0.97× | 0.77× | ||
| Q1 25 | 0.93× | 0.73× | ||
| Q4 24 | 0.89× | 0.75× | ||
| Q3 24 | 0.90× | — | ||
| Q2 24 | 0.87× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HR
| Rental income | $267.6M | 96% |
| Other | $11.4M | 4% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
